Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 19Stomach Neoplasms 12Colorectal Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 6Esophageal Squamous Cell Carcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Spinocerebellar Degenerations 1Sarcoma 1Salivary Gland Malignant Neoplasms 1Resectable NSCLC 1Recurrence 1Rare Tumor 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1NSCLC 1Microsatellite Stable Metastatic Colorectal Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

Gemcitabine 7Oxaliplatin 6Cisplatin 5durvalumab 3130-nm albumin-bound paclitaxel 3pembrolizumab 2Leucovorin 2Drug Therapy 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1sintilimab 1pertuzumab 1anlotinib 1Trastuzumab 1Taxes 1Standard of Care 1Platinum 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Long-Term Synaptic Depression 1Irinotecan 1Folfox protocol 1Fluorouracil 1Everolimus 1Commerce 1Cholangiopancreatography, Endoscopic Retrograde 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gallbladder Neoplasms × sintilimab × Clear all
NCT05757336 2023-03-07

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Fudan University

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡